ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Status:
Recruiting
Trial end date:
2028-01-25
Target enrollment:
Participant gender:
Summary
This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper
Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade
non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients
will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a
Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the
long term (non intervention) follow up phase with the specific duration depending on the
patient's response to treatment